MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
TherapeuticsMD EBITDA 2011-2026 | TXMD
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA TherapeuticsMD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.6 M | 2.38 M | -78.8 M | -154 M | -151 M | -130 M | -77.4 M | -90.1 M | -85.1 M | -54 M | -25.8 M | -16.1 M | -5.37 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.38 M | -154 M | -67.1 M |
Quarterly EBITDA TherapeuticsMD
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -766 K | -599 K | -776 K | - | -1.04 M | -2.61 M | -1.01 M | - | - | -2.34 M | -2.64 M | - | -14.3 M | -14.7 M | -17.5 M | -35.4 M | -36.8 M | -33.1 M | -28.3 M | -34.6 M | -24.7 M | -44.8 M | -49.9 M | - | -26.9 M | -41.5 M | -38 M | - | -34.3 M | -33 M | -24.7 M | - | -14.8 M | -19.8 M | -21.2 M | - | -25.1 M | -21.2 M | -21 M | - | -19.5 M | -27.2 M | -20.9 M | - | -17.8 M | -10.9 M | -8.94 M | - | -7.2 M | -5.61 M | -4.93 M | 28.8 K | -3.9 M | -3.96 M | -2.85 M | - | -1.4 M | -1.02 M | -758 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.8 K | -49.9 M | -17.1 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Drug manufacturers industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
6.82 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-23.6 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-40 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-95.6 M | $ 1.26 | -1.94 % | $ 136 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-16.6 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
-176 M | $ 2.67 | 0.57 % | $ 1.42 B | Canada |
 |
Agile Therapeutics
AGRX
|
-19.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
-260 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
81.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
-601 M | $ 13.18 | -1.35 % | $ 675 M | USA |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Athenex
ATNX
|
-65.5 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-39.7 M | $ 21.49 | 0.05 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
-29.1 M | $ 5.5 | -4.12 % | $ 341 M | USA |
 |
Harrow Health
HROW
|
1.49 M | $ 49.05 | -3.9 % | $ 1.6 B | USA |
 |
China Pharma Holdings
CPHI
|
-1.97 M | $ 1.31 | -3.32 % | $ 22.9 M |  China |
 |
Jupiter Wellness
JUPW
|
429 K | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.72 | -0.41 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
12.3 M | $ 4.18 | -0.83 % | $ 550 M | USA |
 |
Bausch Health Companies
BHC
|
2.23 B | $ 7.79 | 0.13 % | $ 2.84 B | Canada |
 |
Lannett Company
LCI
|
-142 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.64 | 0.01 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.57 M | $ 3.77 | -0.28 % | $ 4.68 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
3.06 M | $ 4.77 | -1.24 % | $ 67.1 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-52.3 M | - | - | $ 193 M | Canada |
 |
Tilray
TLRY
|
-1.37 B | $ 9.42 | 3.14 % | $ 5.82 B | Canada |
 |
Aurora Cannabis
ACB
|
-283 M | $ 4.3 | 0.59 % | $ 86.3 M | Canada |
 |
Veru
VERU
|
-36.6 M | $ 2.39 | 3.46 % | $ 322 M | USA |
 |
Pacira BioSciences
PCRX
|
5.41 M | $ 22.6 | -13.16 % | $ 1.05 B | USA |
 |
PetIQ
PETQ
|
81.6 M | - | 1.64 % | $ 400 M | USA |
 |
cbdMD
YCBD
|
-2.86 M | $ 1.04 | -3.7 % | $ 4.49 M | USA |
 |
Perrigo Company plc
PRGO
|
439 M | $ 14.85 | 0.99 % | $ 2.04 B | USA |
 |
ProPhase Labs
PRPH
|
28.3 M | - | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
4.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Radius Health
RDUS
|
-53.2 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
-5.23 M | $ 0.96 | -2.11 % | $ 22.4 M | USA |
 |
Relmada Therapeutics
RLMD
|
-104 M | $ 4.41 | -0.45 % | $ 133 M | USA |
 |
OptiNose
OPTN
|
-22.3 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-215 M | $ 9.25 | -0.64 % | $ 657 M | USA |
 |
PLx Pharma
PLXP
|
-40.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-127 M | $ 5.37 | 1.13 % | $ 219 M | USA |
 |
SCYNEXIS
SCYX
|
73.2 M | $ 0.66 | -0.66 % | $ 31.6 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Viatris
VTRS
|
4.64 B | $ 12.66 | 0.46 % | $ 15.3 B | USA |
 |
Zomedica Corp.
ZOM
|
-30.8 M | - | -0.21 % | $ 98 M | USA |